Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL7593901

O=C([O-])C(F)(F)F.O=C([O-])C(F)(F)F.[Pd+2].c1ccc(P(c2ccccc2)c2ccccc2)cc1.c1ccc(P(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.52
CYP3A4 P08684 1/20 0.52
ESR1 P03372 2/20 0.46
ESR2 Q92731 2/20 0.46
CES1 P23141 7/20 0.45
CA2 P00918 1/20 0.38
CA4 P22748 1/20 0.38
PTPN1 P18031 1/20 0.34
FAAH O00519 3/20 0.34
HDAC6 Q9UBN7 1/20 0.34
CES2 O00748 1/20 0.33
KDM4E B2RXH2 1/20 0.33
GAA P10253 1/20 0.33
CPA1 P15085 1/20 0.33
KCNN1 Q92952 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL29254212 1.00 TDP1 (0.52) TDP1CYP3A4ESR1ESR2CES1
Trifluoroacetic Acid SCHEMBL8055878 0.96 TDP1 (0.52) TDP1CYP3A4ESR1ESR2CES1
Trifluoroacetic Acid SCHEMBL28345062 0.96 TDP1 (0.52) TDP1CYP3A4ESR1ESR2CES1
Trifluoroacetic Acid SCHEMBL9798368 0.92 TDP1 (0.48) TDP1CYP3A4ESR1ESR2CES1
Trifluoroacetic Acid SCHEMBL8364947 0.86 CYP3A4 (0.57) TDP1CYP3A4ESR1ESR2CES1
Trifluoroacetic Acid SCHEMBL27963324 0.86 CYP3A4 (0.57) TDP1CYP3A4ESR1ESR2CES1
Trifluoroacetic Acid SCHEMBL30195537 0.84 CYP3A4 (0.55) TDP1CYP3A4ESR1ESR2CES1
Trifluoroacetic Acid SCHEMBL18425261 0.84 CYP3A4 (0.55) TDP1CYP3A4ESR1ESR2CES1
Trifluoroacetic Acid SCHEMBL11783673 0.84 CYP3A4 (0.55) TDP1CYP3A4ESR1ESR2CES1
Trifluoroacetic Acid SCHEMBL31532238 0.84 CYP3A4 (0.55) TDP1CYP3A4ESR1ESR2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4584309-A1 POLYCYCLIC-OLEFINIC POLYMERS CONTAINING ACRYLATE FUNCTIONALITY WITH ACRYLATE/MALEIMIDE CROSSLINKERS AS B-STAGEABLE COMPOSITIONS FOR LOW LOSS APPLICATIONS Promerus, LLC (US) 2025-07-16 EP claimed
CN-119968406-A Polycyclic olefin polymers containing acrylate functionality and acrylate/maleimide crosslinkers as B-stageable compositions in low loss applications 普罗米鲁斯有限责任公司 2025-05-09 CN claimed
WO-2024054548-A1 POLYCYCLIC-OLEFINIC POLYMERS CONTAINING ACRYLATE FUNCTIONALITY WITH ACRYLATE/MALEIMIDE CROSSLINKERS AS B-STAGEABLE COMPOSITIONS FOR LOW LOSS APPLICATIONS PROMERUS, LLC (US) 2024-03-14 WO claimed
US-11845880-B2 Polycyclic-olefinic compositions for low-loss films having improved thermal properties PROMERUS, LLC (US) 2023-12-19 US claimed
EP-4237461-A1 SHELF LIFE STABLE AND IMPROVED MASS POLYMERIZABLE POLYCYCLIC-OLEFINIC COMPOSITIONS Promerus, LLC (US) 2023-09-06 EP claimed
EP-4237460-A1 POLYCYCLIC-OLEFINIC COMPOSITIONS FOR LOW-LOSS FILMS HAVING IMPROVED THERMAL PROPERTIES Promerus, LLC (US) 2023-09-06 EP claimed
CN-116368165-A Polycyclic olefin composition for low loss films with improved thermal properties 普罗米鲁斯有限责任公司 2023-06-30 CN claimed
CN-115650814-A Method for efficiently dehalogenating aliphatic hydrocarbon halogenated compound 万华化学集团股份有限公司 2023-01-31 CN claimed
US-20220135831-A1 POLYCYCLIC-OLEFINIC COMPOSITIONS FOR LOW-LOSS FILMS HAVING IMPROVED THERMAL PROPERTIES PROMERUS, LLC (US) 2022-05-05 US claimed
WO-2022094232-A1 POLYCYCLIC-OLEFINIC COMPOSITIONS FOR LOW-LOSS FILMS HAVING IMPROVED THERMAL PROPERTIES PROMERUS, LLC (US) 2022-05-05 WO claimed
WO-2022094236-A1 SHELF LIFE STABLE AND IMPROVED MASS POLYMERIZABLE POLYCYCLIC-OLEFINIC COMPOSITIONS PROMERUS, LLC (US) 2022-05-05 WO claimed
US-20220135832-A1 SHELF LIFE STABLE AND IMPROVED MASS POLYMERIZABLE POLYCYCLIC-OLEFINIC COMPOSITIONS PROMERUS, LLC (US) 2022-05-05 US claimed
EP-4612126-A1 COMPOSITIONS INCLUDING A MIXTURE OF ISOMERS OF ITACONIMIDE NORBORNENE AND CITRACONIMIDE NORBORNENE 3M Innovative Properties Company (US) 2025-09-10 EP disclosed
EP-4584308-A1 POLYCYCLIC-OLEFINIC POLYMERS CONTAINING OLEFINIC FUNCTIONALITY FOR FORMING LOW-LOSS FILMS HAVING IMPROVED THERMAL PROPERTIES Promerus, LLC (US) 2025-07-16 EP disclosed
EP-4584324-A1 FLAME RETARDANT COMPOSITIONS CONTAINING POLYCYCLIC-OLEFINIC POLYMER WITH OLEFINIC FUNCTIONALITY FOR FORMING LOW-LOSS FILMS HAVING IMPROVED DIELECTRIC AND THERMAL PROPERTIES Promerus, LLC (US) 2025-07-16 EP disclosed
EP-4584309-A1 POLYCYCLIC-OLEFINIC POLYMERS CONTAINING ACRYLATE FUNCTIONALITY WITH ACRYLATE/MALEIMIDE CROSSLINKERS AS B-STAGEABLE COMPOSITIONS FOR LOW LOSS APPLICATIONS Promerus, LLC (US) 2025-07-16 EP disclosed
US-20220135831-A1 POLYCYCLIC-OLEFINIC COMPOSITIONS FOR LOW-LOSS FILMS HAVING IMPROVED THERMAL PROPERTIES PROMERUS, LLC (US) 2022-05-05 US disclosed
WO-2022094236-A1 SHELF LIFE STABLE AND IMPROVED MASS POLYMERIZABLE POLYCYCLIC-OLEFINIC COMPOSITIONS PROMERUS, LLC (US) 2022-05-05 WO disclosed
US-6384282-B2 CATALYST IS REACTION PRODUCT OF GROUP 8 METAL AND LIGAND YALE UNIVERSITY 2002-05-07 US disclosed
US-20020016509-A1 Transition metal-catalyzed process for addition of amines to carbon-carbon double bonds YALE UNIVERSITY 2002-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020016509-A1 Transition metal-catalyzed process for addition of amines to carbon-carbon double bonds COASY, CMA1, ATIC TDP1 3430/4885CYP3A4 51/4885ESR1 896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.